Research Reflections: Tarantino Tackles the Implications of ASCO 2022 Data in Breast Cancer

In Partnership With:

Partner | Cancer Centers | <b>Dana-Farber Cancer Institute</b>

Dr Tarantino discusses practice-changing findings in breast cancer and emphasizes the ways in which positive study data can improve the breast cancer treatment paradigm going forward.

Welcome to OncLive On Air®! I’m your host today, Caroline Seymour.

OncLive On Air® is a podcast from OncLive®, which provides oncology professionals with the resources and information they need to provide the best patient care. In both digital and print formats, OncLive® covers every angle of oncology practice, from new technology to treatment advances to important regulatory decisions.

In today’s episode, we welcomed back Paolo Tarantino, MD, a researcher at the European Institute of Oncology in Milan, Italy, and a clinical research fellow at Dana-Farber Cancer Institute in Boston, Massachusetts.

In our exclusive interview, Tarantino discussed practice-changing findings in breast cancer that were presented at the 2022 ASCO Annual Meeting. He highlighted data from the phase 3 DESTINY-Breast04 trial (NCT03734029), in which fam-trastuzumab deruxtecan-nxki (Enhertu) elicited a median progression-free survival (PFS) of 10.1 months vs 5.4 months with physician’s choice of chemotherapy in patients with hormone receptor (HR)–positive, HER2-low metastatic breast cancer.

Tarantino also spoke about the results of the phase 3 TROPiCS-02 trial (NCT03901339), which showed promising results with sacituzumab govitecan-hziy (Trodelvy) in heavily pretreated patients with HR-positive, HER2-negative metastatic breast cancer. He emphasized the ways in which these positive studies can improve the breast cancer treatment paradigm going forward.


That’s all we have for today! Thank you for listening to this episode of OncLive On Air®. Check back on Mondays and Thursdays for exclusive interviews with leading experts in the oncology field.

For more updates in oncology, be sure to visit and sign up for our e-newsletters.

OncLive® is also on social media. On Twitter, follow us at @OncLive and @OncLiveSOSS. On Facebook, like us at OncLive and OncLive State of the Science Summit and follow our OncLive page on LinkedIn.

If you liked today’s episode of OncLive On Air®, please consider subscribing to our podcast on Apple Podcasts, Spotify, Google Podcasts, Amazon Music, and many of your other favorite podcast platforms,* so you get a notification every time a new episode is posted. While you are there, please take a moment to rate us!

Thanks again for listening to OncLive On Air®.

*OncLive On Air® is available on: Apple Podcasts, Google Podcasts, Spotify, Amazon Music, Audacy, CastBox, Deezer, iHeart, JioSaavn, Listen Notes, Player FM, Podcast Addict, Podchaser, RadioPublic, and TuneIn.